Table 1 Comparison of Ki67 status and characteristics in both training and test HCC patients
From: Added value of CE-CT radiomics to predict high Ki-67 expression in hepatocellular carcinoma
Characteristic | Model derivation and verification | Model application | P | |
|---|---|---|---|---|
Training set (n = 120) | Internal test set (n = 51) | External validation set (n = 37) | ||
Sex | 0.255 | |||
Male | 105 | 41 | 27 | |
Female | 15 | 10 | 10 | |
Age | 56.55 ± 9.53 | 56.14 ± 10.82 | 58.32 ± 9.88 | 0.804 |
Etiology | 0.606 | |||
HBV/HCV | 107 | 47 | 19 | |
None or other | 13 | 4 | 18 | |
Serum AFP | 0.995 | |||
Normal | 47 | 20 | 8 | |
Abnormal | 73 | 31 | 29 | |
Total bilirubin (nmol/L) | 17.15(11.43–32.04) | 17.11(11.71–31.15) | 15.8(12.0–19.75) | 0.828 |
ALB(g/l) | 37.85(32.00–42.10) | 37.80(31.80–42.10) | 43.5(39.55–45.05) | 0.412 |
CA199(ng/ml) | 19.89(10.44–45.11) | 19.90(13.42–46.1) | 16.84(10.59–26.21) | 0.446 |
CEA (ng/ml) | 2.53(1.78–3.69) | 2.63(1.89–3.65) | 2.11(1.61–4.13) | 0.056 |